Pharmafile Logo

Dexcom

- PMLiVE

Dexcom and Fitbit team up to tackle diabetes management

Will develop a wearable blood glucose tracking product

- PMLiVE

AZ gets US green light for new Bydureon formulation

Its latest injectable suspension proven to reduce blood sugar levels

- PMLiVE

J&J seeks US OK to add CV claim to Invokana label

If approved the treatment could better compete with rivals Jardiance and Victoza

- PMLiVE

Novo’s semaglutide beats Lilly’s Trulicity in diabetes contest

Analysts predict the drug could be worth $8.7bn in the next five years

- PMLiVE

Type 2 diabetes market set to soar to $64bn by 2026

Rising prevalence, progressive nature and diagnosis of the condition behind the surge

Roche acquires digital diabetes management platform

Will integrate mySugr within its new patient-centred health services arm

- PMLiVE

FDA panel backs CV claims for Novo Nordisk’s Victoza

LEADER trial shows the diabetes treatment reduces risk of cardiovascular death by 13%

- PMLiVE

Trial of J&J’s canagliflozin boosts SGLT2 cardiovascular credentials

Invokana cuts risk of heart failure hospitalisation by a third

- PMLiVE

Novo says real-world data backs its insulin switching

EU-TREAT study shows Tresiba improved blood glucose control

Research Partnership launches new patient Living With Non-alcoholic Steatohepatitis (NASH) report

Living with Non-alcoholic Steatohepatitis (NASH) is a study conducted amongst 100 adults with NASH in the US. The study employs a mixed quantitative/qualitative methodology and will be available to purchase...

Research Partnership

- PMLiVE

Novo seeks to strengthen Tresiba label in US

Studies find insulin degludec advantage over insulin glargine

- PMLiVE

Payback time nears as Sanofi gets CHMP backing for biosimilar Humalog

Panel recommends insulin Lispro Sanofi to treat diabetes

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links